...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

yep, been saying this for a while now Koo.

Wouldnt matter if there were 10 trials going on IMO.How can we share in Don's excitment or get jacked about any news & all the while he continues to fill his pockets?

Yes, ive been told ,just hang in there another 2-5 years buddy,heck maybe more but we will get there.

I'm truly hoping BP steps in this year.

& why dont some of these people taking part in these PP's try & go after a few hundred thousand shares at .20,.30,.40 .50 - 60 cents US on this mighty "expert market"??? What gives there?? It makes zero cents to me - i mean heck,why wouldnt they fill their boots or min top em off at this ridiculous price??

 

Share
New Message
Please login to post a reply